Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty.
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Theoretical concentration curve at a half-life of 3 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Trelstar provides an effective option for hormonal suppression therapy in advanced prostate cancer — the 6-month formulation reduces treatment frequency to two injections per year.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy